Back to results
US 9,435,870 B2Granted
Methods, systems and computer programs for assessing CHD risk using adjusted HDL particle number measurements
AssigneeLipoScience, Inc.
InventorJames D. Otvos
Life of this patent
Estimating the term…
Abstract
Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.
Claims33
A method of determining a subject's risk of having and/or developing coronary heart disease, comprising:
- conducting Nuclear Magnetic Resonance to obtain concentration measurements of small and large High Density Lipoprotein subclass particles from a single in vitro blood plasma or serum sample of a subject;
- and
- programmatically numerically adjusting at least one of the obtained small and large High Density Lipoprotein subclass particle concentration measurements of the single in vitro blood plasma and/or serum sample based on a predetermined mathematical model with at least one weighting factor that is multiplied to increase or decrease the small and/or large High Density Lipoprotein subclass particle concentration measurements, wherein the at least one weighting factor reflects predicted CHD risk for the weighted High Density Lipoprotein subclass, to yield a High Density Lipoprotein risk number that can be greater than a summation of an actual, unadjusted total High Density Lipoprotein particle concentration measurement, to thereby determine the subject's High Density Lipoprotein based risk of coronary heart disease.
A method for determining a subject's risk of coronary heart disease, comprising:
- conducting Nuclear Magnetic Resonance to obtain concentration measurements of small and large High Density Lipoprotein subclass particles in a biosample of interest;
- multiplying a weighting factor by at least one of the measured large and small High Density Lipoprotein particle concentrations;
- and
- calculating a High Density Lipoprotein risk number using the weighted High Density Lipoprotein particle concentration(s), wherein the High Density Lipoprotein risk number is a discrete parameter separate from actual High Density Lipoprotein subclass particle concentrations and that is different from a summation of the obtained actual small and large High Density Lipoprotein particle concentration measurements,
- wherein the obtaining, multiplying and calculating steps are carried out using at least one processor.
2 more elements
A computer program product for adjusting measured in vitro concentrations of High Density Lipoprotein particles to assess coronary heart disease risk, the computer program product comprising:
- a non-transitory computer readable storage medium having embodied in said medium computer readable program code that:
- (i) deconvolutes at least one Nuclear Magnetic Resonance signal of a patient biosample into measured concentrations of small and large High Density Lipoprotein particle subclasses;
- and
- (ii) adjusts concentration measurements of at least one of small and large High Density Lipoprotein particle subclasses of a biosample to generate a High Density Lipoprotein risk number to reflect a subject's risk of having or developing coronary heart disease, wherein the High Density Lipoprotein risk number is calculated based on a defined mathematical model to yield a numerical High Density Lipoprotein risk number that is different from a summation of the obtained actual small and large High Density Lipoprotein particle concentration measurements.
1 more element
A system for obtaining data regarding lipoprotein constituents in a subject, comprising:
- a Nuclear Magnetic Resonance spectrometer for acquiring at least one Nuclear Magnetic Resonance spectrum of an in vitro blood, plasma or serum sample from a subject;
- and
- at least one processor in communication with the Nuclear Magnetic Resonance spectrometer, the at least one processor configured to:
- determine concentrations of small and large High Density Lipoprotein particle subclasses in the sample;
- and
- multiply at least one weighting factor by at least one of the determined small and large High Density Lipoprotein particle concentrations of the sample and sum weighted and unweighted concentrations to yield a numerical High Density Lipoprotein risk number for the sample that is different from a summation of the obtained actual small and large High Density Lipoprotein particle concentration measurements to determine a subject's risk of developing or having coronary heart disease.
3 more elements
A method of evaluating a person's risk of having or developing coronary heart disease, comprising:
- electronically calculating a High Density Lipoprotein risk number for a person using a summation of at least two of small, medium and large High Density Lipoprotein particle concentration values of a biosample from the person, wherein at least one of the concentration values for the summation for the sample is electronically increased, using a processor, relative to the measured small High Density Lipoprotein particle concentration value using a predefined weighting factor, wherein the High Density Lipoprotein risk number can have a concentration value that is greater than a total actual High Density Lipoprotein subclass concentration measurement.
A method of assessing coronary heart disease risk in a patient, comprising:
- generating a single risk predictor variable using a ratio of a Low Density Lipoprotein particle number as a numerator and a High Density Lipoprotein particle number as a denominator, wherein the generating step is carried out using at least one processor, and wherein the Low Density Lipoprotein and High Density Lipoprotein particle numbers are calculated using at least one predefined weighting factor that is multiplied by an actual concentration measurement of at least one subclass of respective Low Density Lipoprotein and High Density Lipoprotein particle subclasses, wherein the multiplied concentration of at least one subclass of respective Low Density Lipoprotein and High Density Lipoprotein particle subclasses increases or decreases actual concentrations of the Low Density Lipoprotein particle number and the High Density Lipoprotein particle number and are different from a summation of total Low Density Lipoprotein particle number and total High Density Lipoprotein particle number.
Dependencies are inferred from the claim text.